三代测序实现新发变异与不完整家系单基因病胚胎植入前遗传学检测
本研究纳入北京大学第三医院16个需行PGT-M的新发变异或不完整家系,仅对先证者行全基因组三代测序构建单体型。全部16个家系成功构建单体型,14个完成胚胎检测,简化流程与标准三代测序策略诊断结果完全一致。该方法可扩大PGT-M适用范围并提升临床效率。
要点
- 仅用先证者三代测序数据即可构建可靠单体型,无需额外家系成员样本。
- 简化流程与标准三代测序策略在剩余胚胎中诊断结果完全一致。
- 适用性受胚胎染色体整倍性及信息性SNP获取是否充分限制。
核心结论
- 先证者全基因组三代测序直接构建单体型,可为新发变异或不完整家系提供简化的PGT-M流程。
研究设计与样本
- 前瞻性研究,2023年7月至2025年8月于北京大学第三医院生殖医学中心纳入16个需PGT-M的家系。
- 纳入9个不完整家系与7个新发变异家系,覆盖10个不同致病基因或区域。
主要发现
- 三代测序相位块对绝大多数OMIM基因覆盖超过75%,多数含100个以上位于基因体及1 Mb侧翼区的杂合信息性SNP。
- 16个家系全部成功构建单体型,14个家系完成胚胎检测,2个因个人原因退出。
- 3个家系经羊膜腔穿刺产前诊断确认胎儿不携带致病变异。
- 简化策略在非D4Z4家系与D4Z4家系胚胎中适用率分别为91.9%和80.0%。
- 部分胚胎因非整倍体或SNP信息不足无法诊断,其余胚胎诊断结果与标准三代测序策略完全一致。
临床怎么用
- 对新发变异或不完整家系,可仅采集先证者行全基因组三代测序构建单体型后开展PGT-M。
- 在适用范围内可采用简化流程,将先证者单体型杂合SNP与胚胎对应纯合位点比对推断遗传状态。
局限性
- 方法适用性主要取决于胚胎染色体整倍性和信息性SNP的充分获取。
- 全基因组三代测序成本较高,限制广泛推广。
- 队列样本量有限(n=16),需在更大临床人群中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can preimplantation genetic testing for monogenic defects (PGT-M) be achieved by performing third-generation sequencing (TGS) only on the proband for families with de novo variants or incomplete pedigrees? SUMMARY ANSWER: Whole-genome TGS facilitates a simplified PGT-M workflow by establishing reliable haplotypes solely from proband sequencing involving de novo variants or incomplete pedigrees. WHAT IS KNOWN ALREADY: PGT-M enables the accurate exclusion of embryos carrying pathogenic variants. However, its application to de novo variants or incomplete pedigrees is hindered by haplotype phasing. Moreover, direct variant detection suffers from detection failure and erroneous genotyping due to uneven coverage and allele dropout caused by whole-genome amplification. Current solutions, such as gamete or embryo analysis and targeted TGS, remain constrained by procedural complexity and lack of universality across different genes and mutation types. STUDY DESIGN, SIZE, DURATION: This prospective study enrolled 16 families requiring PGT-M with de novo variants or incomplete pedigrees at the Reproductive Medicine Center of Peking University Third Hospital from July 2023 to August 2025. PARTICIPANTS/MATERIALS, SETTING, METHODS: This study included 9 families with incomplete pedigrees and 7 families with de novo variants, covering 10 distinct disease-causing genes or regions. To assess the capability of TGS for haplotype phasing, we evaluated its performance regarding genomic coverage and the retrieval of informative single-nucleotide polymorphisms (SNPs). Haplotypes were constructed using proband TGS data, and linkage analysis was performed by integrating linked heterozygous SNPs with next-generation sequencing data from the couple and embryos to determine pathogenic status. Subsequently, we developed a simplified strategy that inferred inheritance by comparing heterozygous SNPs from the proband's haplotype directly against corresponding homozygous sites in the embryos. The diagnostic outcomes of this simplified workflow were statistically evaluated and compared with those of the standard TGS strategy to assess concordance. MAIN RESULTS AND THE ROLE OF CHANCE: Phase blocks generated by TGS achieved >75% coverage for the vast majority of OMIM genes, most of which contained more than 100 heterozygous informative SNPs located in the gene body and their 1 Mb flanking regions, indicating a wide range of applicability in a variety of gene variants. Haplotypes were successfully constructed for all 16 enrolled families using TGS data, with 14 families having completed embryo testing, while the 2 families withdrew due to personal reasons. To date, prenatal diagnosis via amniocentesis in three families has confirmed the fetuses to be free of pathogenic variants. A simplified strategy was further applied to 14 families that completed the embryo testing process. This approach achieved applicability rates of 91.9% and 80.0% in embryos from non-D4Z4 and D4Z4 families, respectively. While diagnosis was precluded in a subset of embryos due to aneuploidy or insufficient SNP retrieval, the diagnostic outcomes for all remaining embryos were fully concordant with those of the standard TGS strategy. LIMITATIONS, REASONS FOR CAUTION: The applicability of this approach is primarily contingent upon embryo chromosomal euploidy and sufficient retrieval of informative SNPs. Additionally, the relatively high cost of whole-genome TGS remains a barrier to widespread adoption. Given the limited cohort size (n = 16) of this study, the applicability of this method necessitates further validation in larger clinical populations. WIDER IMPLICATIONS OF THE FINDINGS: Direct haplotype construction via proband whole-genome TGS provides an effective clinical strategy to expand the applicability of PGT-M, particularly for families with de novo variants or incomplete pedigrees. Furthermore, the simplified TGS workflow demonstrates the potential to improve clinical efficiency and reduce costs relative to the standard TGS protocol within its applicable scope. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Natural Science Foundation of China (82125013, 82288102, 825B2046). The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Fang Y, Wang Y, Zhan Y, et al. Third-generation sequencing enables accurate preimplantation genetic testing of monogenic defects for de novo variants and incomplete pedigrees. Hum Reprod. 2026. PMID: 42217180. doi:10.1093/humrep/deag082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。